(1 - 22 von 26
)
MOLN.S - Molecular Partners AG | Stock Price & Latest News | Reuters
www.reuters.com
Nicolas Leupin: Chief Medical Officer, Member of the Management Board. Agnete B. Fredriksen: Non-Executive Independent Director.
onkoserv - der aktuellste und unabhängige deutsche Informationsdienst...
www.onkoserv.de
Onkoserv ist der aktuellste deutsche Informationsdienst für die klinische Onkologie
Siric Brio organizes a conference on May the 11st, 2017, 14:30-15:20,...
trail.labex.u-bordeaux.fr
Nicolas Leupin is a medical oncologist with a special interest in hematological oncology and will give this lecture in Salle des conférences, Bâtiment Espace...
265 wollen einen Sitz im Stadtparlament ergattern - Freiburger...
www.freiburger-nachrichten.ch
Achtzig Sitze gibt es im Freiburger Generalrat zu besetzen. Auf acht Listen kandidieren 265 Leute; darunter sind 83 Frauen. Zum ersten Mal treten in der Stadt...
ARGEN-X (EBR:ARGX) argenx to present complete data from the Phase 2...
www.webdisclosure.com
... from current therapies for managing IgG levels, including plasmapheresis, where benefit reversed more rapidly," commented Nicolas Leupin, CMO of argenx.
ArgenX reports hints to efficacy of ARGX-113 in generalised...
european-biotechnology.com
... evaluating in our two ongoing Phase II studies in immune thrombocytopenia and pemphigus vulgaris," said ArgenX's CMO Nicolas Leupin.
Argenx Starts Trial in Cutaneous T-cell Lymphoma Patients of ARGX-110
lymphomanewstoday.com
... cohort, resulting in several patients with partial response or stable disease,” Nicolas Leupin, CMO of argenx, said in a news release.
Dutch Life Science Database
www.dutchlifescience.com
Search the Dutch Life Science Database and identify potential partners in the Dutch Biotech, Pharma and Medtech industry
Platelet Disorder Support Association - for People with ITP - argenx...
www.pdsa.org
"argenx, a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe...
arGEN X : argenx launches Phase II proof-of-concept clinical trial of...
www.marketscreener.com
Interim data expected in H September 26, Breda, the Netherlands / Ghent, Belgium - argenx , a clinical-stage biotechnology company developing a...
Subcutaneous ARGX-113 Trial Underway for MG, Autoimmune Diseases
myastheniagravisnews.com
The first volunteer has been dosed in a trial evaluating argenx's subcutaneous formulation of ARGX-113 for autoimmune diseases such as myasthenia gravis.
UZH - Life Science Zurich Young Scientist Network - Zurich Life...
www.lifescience-youngscientists.uzh.ch
Initial Data on Candidate for Autoimmune Disease Reported - Lupus...
lupusnewstoday.com
Read more about argenx Reports Initial Data from Phase 1 Study of ARGX-113 in Healthy Volunteers
argenx reports interim data from first cohort of Phase 2
www.globenewswire.com
body { font-family: Arial, Verdana, Helvetica; font-size: 13px;}
table.hugin { border-color:black;}
td.hugin { padding: 3px;...
argenx announces new cusatuzumab (ARGX-110) AML data in abstracts...
apnews.com
... to offer a novel mechanism of action in AML against leukemic blasts and leukemic stem cell compartments,” commented Nicolas Leupin, MD, ...
argenx begins dosing in Phase III myasthenia gravis trial
www.clinicaltrialsarena.com
argenx chief medical officer Nicolas Leupin said: “The dosing of the first patient represents an important milestone in advancing efgartigimod ...
Molecular Partners ernennt neuen medizinischen Leiterwww.bio-technopark.ch › news › molecular-partners-ernennt-neuen-mediz...
www.bio-technopark.ch
Schlieren ZH - Das Schlieremer Biotechnologieunternehmen Molecular Partners hat Nicolas Leupin zum neuen medizinischen Leiter ernannt.
Molecular Partners prüft Anti-Corona-Präparat am Menschen - punkt4punkt4.info › social-news › news › molecular-partners-prueft-anti-corona-...
punkt4.info
... sowohl infizierte Patienten zu behandeln als auch Hochrisikopopulationen zu schützen“, wird Nicolas Leupin, Chief Medical Officer von Molecular Partners ...
argenx reaches 50% enrollment in Phase 2 clinical trial of ARGX ...www.lspvc.com › news › argenx-reaches-50-enroll...
www.lspvc.com
"We are encouraged by the pace of enrollment in this trial," commented Nicolas Leupin, Chief Medical Officer of argenx. "We now expect to present the ...
argenx reports interim data from first cohort of Phase 2 proof LSPvcwww.lspvc.com › news › argenx-reports-interim-dat...
www.lspvc.com
... control as characterized by the start of healing of existing lesions and absence of formation of new lesions," commented Nicolas Leupin, CMO of argenx.
Molecular Partners begins patient dosing in phase 1 study of ...www.pharmabiz.com › NewsDetails
www.pharmabiz.com
— ... both treat infected patients and protect high risk populations,” said Nicolas Leupin, M.D., chief medical officer of Molecular Partners.
Molecular Partners to Host Oncology Day (Virtual)
www.globenewswire.com
— Nicolas Leupin, MD, PhD, CMO of Molecular Partners. AML: Emerging treatment landscape and the targeting of leukemic stem cells.
sortiert nach Relevanz / Datum